[
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Up As Oracle Soars; Cathie Wood Buys Buffett Stock Amid 145% Run (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rose as Nvidia shined. Oracle soared and Cathie Wood bought a Warren Buffett stock. Hims & Hers stock dived.",
    "url": "https://finnhub.io/api/news?id=bafa44a6fb358264e5905c62eb19f3ddfe799792298b75da6545fe137513e964",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770673331,
      "headline": "Stock Market Today: Dow Up As Oracle Soars; Cathie Wood Buys Buffett Stock Amid 145% Run (Live Coverage)",
      "id": 138789435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rose as Nvidia shined. Oracle soared and Cathie Wood bought a Warren Buffett stock. Hims & Hers stock dived.",
      "url": "https://finnhub.io/api/news?id=bafa44a6fb358264e5905c62eb19f3ddfe799792298b75da6545fe137513e964"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Firm As Nvidia, Microsoft Jump; AI Stock Clears Buy Point (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rose as Nvidia and Microsoft shined. An energy stock tested an entry. IBM stock lagged.",
    "url": "https://finnhub.io/api/news?id=d0001a5a9c32ec1a6dd3024d8e884df53475ddf9bee7459e60a533d9859fc66c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770656969,
      "headline": "Stock Market Today: Dow Firm As Nvidia, Microsoft Jump; AI Stock Clears Buy Point (Live Coverage)",
      "id": 138608485,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rose as Nvidia and Microsoft shined. An energy stock tested an entry. IBM stock lagged.",
      "url": "https://finnhub.io/api/news?id=d0001a5a9c32ec1a6dd3024d8e884df53475ddf9bee7459e60a533d9859fc66c"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s ENFLONSIA Approval Expands RSV And Pediatric Growth Story In Canada",
    "summary": "Merck (NYSE:MRK) received Health Canada approval for ENFLONSIA® (clesrovimab) for RSV prevention in newborns and infants. The decision introduces a new option in Canada for protecting vulnerable pediatric patients against RSV. For investors watching Merck, this Canadian approval adds another product to its infectious disease portfolio while the stock trades around $121.93. Shares are up 7.6% over the past week, 10.3% over the past month, and 14.5% year to date, with a 46.4% return over the...",
    "url": "https://finnhub.io/api/news?id=7c746419a761e2ee152f559fcaa9ed2ae6803c8f2744563287d203bfa4203d02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770656958,
      "headline": "Merck’s ENFLONSIA Approval Expands RSV And Pediatric Growth Story In Canada",
      "id": 138609127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) received Health Canada approval for ENFLONSIA® (clesrovimab) for RSV prevention in newborns and infants. The decision introduces a new option in Canada for protecting vulnerable pediatric patients against RSV. For investors watching Merck, this Canadian approval adds another product to its infectious disease portfolio while the stock trades around $121.93. Shares are up 7.6% over the past week, 10.3% over the past month, and 14.5% year to date, with a 46.4% return over the...",
      "url": "https://finnhub.io/api/news?id=7c746419a761e2ee152f559fcaa9ed2ae6803c8f2744563287d203bfa4203d02"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
    "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770655080,
      "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
      "id": 138693763,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion",
    "summary": "Eli Lilly  shares rose Monday after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said on Monday.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
    "url": "https://finnhub.io/api/news?id=02bac86869c1d41106201ab84b6bdd9f41e989480cf0ce97807b8d661111a0bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770653100,
      "headline": "Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion",
      "id": 138608836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Eli Lilly  shares rose Monday after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said on Monday.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
      "url": "https://finnhub.io/api/news?id=02bac86869c1d41106201ab84b6bdd9f41e989480cf0ce97807b8d661111a0bf"
    }
  },
  {
    "ts": null,
    "headline": "Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica",
    "summary": "Growth is fueled by the adoption of advanced analytics platforms, AI-driven modules, and cloud-based solutions that optimize drug discovery, clinical trials, pharmacovigilance, and precision medicine. Leading players such as Roche, Johnson & Johnson, AstraZeneca, and Merck are investing heavily in specialized analytics tools and dedicated data teams to accelerate real-time decision-making, improve patient stratification, and enhance treatment outcomes.Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- T",
    "url": "https://finnhub.io/api/news?id=607f9f05b9b9a2daf0dc496291a7821389a2c7a302ce425ec42c736ae4d06a7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770652260,
      "headline": "Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica",
      "id": 138514559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Growth is fueled by the adoption of advanced analytics platforms, AI-driven modules, and cloud-based solutions that optimize drug discovery, clinical trials, pharmacovigilance, and precision medicine. Leading players such as Roche, Johnson & Johnson, AstraZeneca, and Merck are investing heavily in specialized analytics tools and dedicated data teams to accelerate real-time decision-making, improve patient stratification, and enhance treatment outcomes.Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- T",
      "url": "https://finnhub.io/api/news?id=607f9f05b9b9a2daf0dc496291a7821389a2c7a302ce425ec42c736ae4d06a7a"
    }
  },
  {
    "ts": null,
    "headline": "BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?",
    "summary": "BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.",
    "url": "https://finnhub.io/api/news?id=d5a61384b04614f81fd439ef3c9e9f187c46cc0736fb314dddc99557548bae90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770650940,
      "headline": "BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?",
      "id": 138609129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.",
      "url": "https://finnhub.io/api/news?id=d5a61384b04614f81fd439ef3c9e9f187c46cc0736fb314dddc99557548bae90"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Skids Even As Nvidia Jumps; Monday Plunges, Biopharma Funds Lag (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index fell Monday as Wall Street awaited this week's January jobs report. Nvidia shined but Monday plunged.",
    "url": "https://finnhub.io/api/news?id=07c7b7c4eff0c7843c9c8b0f48e4c1474e7bf92d873a963b07b7a9ee13570f1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770650338,
      "headline": "Stock Market Today: Dow Skids Even As Nvidia Jumps; Monday Plunges, Biopharma Funds Lag (Live Coverage)",
      "id": 138514106,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index fell Monday as Wall Street awaited this week's January jobs report. Nvidia shined but Monday plunged.",
      "url": "https://finnhub.io/api/news?id=07c7b7c4eff0c7843c9c8b0f48e4c1474e7bf92d873a963b07b7a9ee13570f1f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises. It’s Acquiring This Cell Therapy Company for $2.4 Billion.",
    "summary": "Eli Lilly  shares rose after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
    "url": "https://finnhub.io/api/news?id=897fc7d1fc2a9b5c1b358911fb66a1c7888a8001934d5d637a7e4674e940d399",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770640440,
      "headline": "Eli Lilly Stock Rises. It’s Acquiring This Cell Therapy Company for $2.4 Billion.",
      "id": 138414694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Eli Lilly  shares rose after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
      "url": "https://finnhub.io/api/news?id=897fc7d1fc2a9b5c1b358911fb66a1c7888a8001934d5d637a7e4674e940d399"
    }
  },
  {
    "ts": null,
    "headline": "Merck: The Spike Doesn't Make It Overvalued",
    "summary": "Merck & Co., Inc. is rated a Buy due to robust asset portfolio, strong shareholder return, and buybacks. Learn more about MRK stock here.",
    "url": "https://finnhub.io/api/news?id=19e8f630f0dc53a45011ede08f17bfdb93cdab497f0f8078ddc73038558e80ac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770643969,
      "headline": "Merck: The Spike Doesn't Make It Overvalued",
      "id": 138640092,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. is rated a Buy due to robust asset portfolio, strong shareholder return, and buybacks. Learn more about MRK stock here.",
      "url": "https://finnhub.io/api/news?id=19e8f630f0dc53a45011ede08f17bfdb93cdab497f0f8078ddc73038558e80ac"
    }
  },
  {
    "ts": null,
    "headline": "Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?",
    "summary": "MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.",
    "url": "https://finnhub.io/api/news?id=1a35d6254c1cfe8e41d231563a4990b459f3671d7ca8cee14afbfb1a56fe537f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770641460,
      "headline": "Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?",
      "id": 138514993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.",
      "url": "https://finnhub.io/api/news?id=1a35d6254c1cfe8e41d231563a4990b459f3671d7ca8cee14afbfb1a56fe537f"
    }
  },
  {
    "ts": null,
    "headline": "Merck: A Buy For 2026, But The Clock Is Still Ticking",
    "summary": "Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total returns. See why MRK stock is a buy.",
    "url": "https://finnhub.io/api/news?id=06ab962b0ed78a0aaaef2054f46f34999dbc8d55632aadef80010e4a8c594f12",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770630933,
      "headline": "Merck: A Buy For 2026, But The Clock Is Still Ticking",
      "id": 138467839,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346050292/image_1346050292.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total returns. See why MRK stock is a buy.",
      "url": "https://finnhub.io/api/news?id=06ab962b0ed78a0aaaef2054f46f34999dbc8d55632aadef80010e4a8c594f12"
    }
  }
]